Methylation subgroup and molecular heterogeneity is a hallmark of glioblastoma: implications for biopsy targeting, classification and therapy.

Many of these large studies which have greatly advanced our understanding of the molecular basis of GB rely, however, on a single biopsy per patient, thereby neglecting the possibly significant contribution of molecular tumor heterogeneity to GB biology.

also in 649 other papers